Growth Metrics

ClearPoint Neuro (CLPT) Cash & Equivalents (2017 - 2026)

ClearPoint Neuro's Cash & Equivalents history spans 14 years, with the latest figure at $45.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 128.36% to $45.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.9 million, a 128.36% increase, with the full-year FY2025 number at $45.9 million, up 128.36% from a year prior.
  • Cash & Equivalents hit $45.9 million in Q4 2025 for ClearPoint Neuro, up from $38.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CLPT hit a ceiling of $64.9 million in Q1 2021 and a floor of $12.4 million in Q1 2025.
  • Historically, Cash & Equivalents has averaged $35.1 million across 5 years, with a median of $30.2 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 293.12% in 2021 and later tumbled 67.56% in 2022.
  • Tracing CLPT's Cash & Equivalents over 5 years: stood at $54.1 million in 2021, then plummeted by 48.98% to $27.6 million in 2022, then decreased by 16.3% to $23.1 million in 2023, then decreased by 12.99% to $20.1 million in 2024, then surged by 128.36% to $45.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for CLPT at $45.9 million in Q4 2025, $38.2 million in Q3 2025, and $41.5 million in Q2 2025.